The company’s PromarkerEndo – to detect endometriosis – and other tests in the pipeline will also benefit from the enhanced capabilities of the new spectrometry platform.
Proteomics International Laboratories managing director Dr Richard Lipscombe said: “Our Company continues to raise its international profile with these achievements. Attaining CLIA/CAP certification is another important milestone in the commercialisation of the Promarker suite of diagnostics. CAP is a universally recognised clinical accreditation that puts Proteomics International firmly on the map as a leading provider of quality precision diagnostics.”
CAP accreditation involves a comprehensive review of laboratory records, quality control procedures, staff qualifications, equipment, facilities, safety programs and overall management.
The process ensures adherence to the highest standards of care, mitigates risk and supports improved patient outcomes.
The company says these developments will significantly strengthen Proteomics International’s position to deliver innovative predictive and prognostic diagnostics in the world’s largest healthcare market.
With CAP accreditation secured alongside its latest spectrometry capabilities, Proteomics International is strongly positioned to accelerate US commercialisation of its Promarker precision diagnostics pipeline.
The upcoming 2026 launch of PromarkerEso represents another milestone along the exhaustive path towards transforming early detection and patient outcomes in esophageal cancer and beyond.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
